Ventricular Fibrillation Market Report 2024

The ventricular fibrillation market size has grown strongly in recent years. It will grow from $5.77 billion in 2023 to $6.13 billion in 2024 at a compound annual growth rate (CAGR) of 6.2%. During the historic period, growth can be attributed to heightened awareness, a greater incidence of heart-related conditions, enhanced healthcare infrastructure, and an increasing prevalence of cardiovascular diseases.

The ventricular fibrillation market size is expected to see strong growth in the next few years. It will grow to $7.84 billion in 2028 at a compound annual growth rate (CAGR) of 6.4%. In the forecast period, growth can be attributed to rising healthcare expenditure, expanding adoption of telemedicine, and an increasing incidence of cardiac-related health issues. Key trends expected in this period include advancements in telemedicine and remote monitoring, expansion of healthcare infrastructure, technological improvements in defibrillation devices, and the integration of artificial intelligence into healthcare practices.

The increasing prevalence of cardiovascular diseases is expected to drive growth in the ventricular fibrillation market. Cardiovascular diseases encompass a range of disorders affecting the heart and blood vessels. Factors contributing to rising disease rates include sedentary lifestyles, unhealthy diets, smoking, obesity, stress, genetics, poor sleep, alcohol consumption, and air pollution. Ventricular fibrillation, a severe manifestation of cardiovascular diseases, often leads to sudden cardiac arrest and significantly contributes to mortality associated with heart conditions. According to the World Heart Federation, cardiovascular disease deaths are projected to rise from 18.9 million in 2020 to over 22.2 million by 2030, and further to 32.3 million by 2050. This trend underscores the driving force behind the ventricular fibrillation market's expansion.

Leading companies in the ventricular fibrillation market are focusing on technological innovation, such as advanced artificial intelligence (AI) algorithms, to improve cardiac diagnostics. These AI algorithms enable machines to analyze data, perform tasks, and make decisions, significantly enhancing the accuracy of detecting atrial fibrillation (AF), a key precursor to stroke. For example, PulseAI, an Ireland-based medical technology firm, recently developed an AI algorithm using machine learning to analyze electrocardiogram readings with high sensitivity and specificity. This innovation aims to detect subtle patterns and anomalies that may indicate cardiovascular disease or other conditions, thereby improving diagnostic accuracy, reducing interpretation errors, and enhancing patient outcomes.

In April 2023, Abbott, a US-based medical device company, acquired Cardiovascular Systems Inc. This acquisition allows Abbott to expand its portfolio of vascular devices, providing more comprehensive solutions for patients with complex cardiovascular conditions. Cardiovascular Systems Inc., based in the US, specializes in developing and commercializing innovative treatments for vascular and coronary diseases.

Major companies operating in the ventricular fibrillation market are Abbott Laboratories, Medtronic plc, GE HealthCare Technologies Inc., Boston Scientific Corporation, Philips Healthcare, St. Jude Medical Inc., Mindray Medical International Limited, ZOLL Medical Corporation, Biotronik, Nihon Kohden Corporation, LivaNova, Fukuda Denshi Co. Ltd., Laerdal Medical Corporation, Schiller AG, Physio-Control, Cardiac Science Corporation, CU Medical Systems Inc., Defibtech LLC, Progetti Srl, HeartSine Technologies, Inovise Medical Inc.

North America was the largest region in the ventricular fibrillation market in 2023. The regions covered in the ventricular fibrillation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ventricular fibrillation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Ventricular fibrillation is a dangerous heart rhythm disorder characterized by rapid and uncoordinated contractions of the heart's lower chambers (ventricles), resulting in inadequate blood flow throughout the body. This condition is a critical medical emergency that demands immediate intervention and can be fatal if not promptly treated.

The management of ventricular fibrillation involves several approaches, such as cardiopulmonary resuscitation (CPR), defibrillation, medication administration, catheter ablation, and left cardiac sympathetic denervation. CPR, also known as cardiopulmonary resuscitation, is a crucial procedure that includes chest compressions and rescue breaths to restore circulation and breathing in individuals whose heart or breathing has ceased. Various diagnostic methods, including electrocardiograms, blood tests, echocardiograms, electrophysiology studies, and x-rays, are employed across different healthcare settings such as hospitals, ambulatory surgical centers, specialty clinics, and others. These techniques aid in the accurate diagnosis and management of ventricular fibrillation.

The ventricular fibrillation market research report is one of a series of new reports that provides ventricular fibrillation market statistics, including ventricular fibrillation industry global market size, regional shares, competitors with a ventricular fibrillation market share, detailed ventricular fibrillation market segments, market trends and opportunities, and any further data you may need to thrive in the ventricular fibrillation industry. This ventricular fibrillation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ventricular fibrillation market consists of revenues earned by entities by providing services such as ventricular fibrillation diagnostics, treatment, management, and support services for hospital and clinic applications. The market value includes the value of related goods sold by the service provider or included within the service offering. The ventricular fibrillation market also includes sales of automated external defibrillators, cardiac monitors, and electrocardiogram (ECG) machines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.